Progression Suppression and Retinal Regression in VEGF-resistant AMD

NCT07005323 | Recruiting DMC

• 1 other identifier: PAL-222-P2
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to assess safety and efficacy in patients with Neovascular Age-related Macular Degeneration with no response to existing therapy. The main measures it aims to answer are:

• Investigation of adverse events
• Changes in clinical testing data
• Changes in vital signs
• Changes in intraocular pressure of the therapeutic eye
• Changes in testing of anterior segment of the therapeutic eye Participants will be implanted one sheet of PAL-222 into the subretinal space through pars plana vitrectomy. Researchers will compare pre and post implantation of therapeutic eye to see if any safety issues recognized

Conditions

Neovascular Age-related Macular Degeneration (AMD)

Outcome Measures

Primary Outcomes (1)

• Safety Evaluation: Incidence, type, and severity of Adverse Events (AE)

  52 weeks

Study Arms (1)

Therapeuitic group

EXPERIMENTAL

One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.

Procedure: Pars plana vitrectomy

Interventions

Pars plana vitrectomy PROCEDURE

One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.

Therapeuitic group

Eligibility Criteria

• Age: 50 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged between 50 and 85 years at the time of consent acquisition
• Patients diagnosed neovascular AMD in one or both eyes
• Patients with corrected letter vision in the subject eye of 20 letters or more (equivalent to decimal vision of 0.05) and less than 60 letters (equivalent to decimal vision of 0.32)
• Patients who apply to one or more of the followings:
• ① RPE defect site in the RPE tear includes the Fovea
• ② The Macular atrophy confirmed by low fundus autofluorescence extends to the fovea
• ③ Patients with choroidal thinning (150 micrometer and less), subretinal fluid resistant to standard treatment, and high activity, but without hard exudated or subretinal hemorrhage which are indicators of the high risk of visual impairment.
• ④ Patients with cystoid macular degeneration with photoreceptor cell loss and intraretinal fluid above fibrovascular pigment epithelial detachment, but without hard exudates or subretinal hemorrhage.
• Patients who had little improvement in exudative changes and no improvement, or deterioration of vision in recent two treatment with VEGF inhibitor therapy (two consecutive administration at 4-8-week intervals), after existing therapy

You may not qualify if:

• Patients with fibrovascular pigment epithelial detachment (thickness 50 µm or more) in the subfoveal area in the subject eye.
• Patients with hard exudates in the subretinal or intraretinal area in the subject eye.
• Patients with eye infections
• Patients with a history of retinal vascular disease other than neovascular AMD, retinal degenerative disease, rhegmatogenous retinal detachment, macular hole, premacular membrane with retinal wall, uveitis, or other ocular inflammatory disease in the subject eye.
• Patients with optic nerve atrophy in the subject eye
• Patients with progressive glaucoma in the subject eye (in whom intraocular pressure is not controlled, or visual field loss is progressive or has already spread to the macula)
• Patients with severe myopia in the subject eye (axial length of 26.5 mm or more, or spherical equivalent of -7.0 D or less in phakic eyes)
• Patients who have undergone intraocular surgery in the subject eye. (In the case of cataract surgery, patients may be enrolled if they have had no endophthalmitis or other complications, have progressed well, and more than 3 months have passed since the surgery)
• Patients with corrected visual acuity of the non-subject eye 0.1 or less
• Patients who are currently receiving or will receive VEGF inhibitor treatment in the non-subject eye during the study period
• Patients with abnormal findings that pose a problem in clinical trial participation in screening tests.
• Patients with positive HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody, syphilis serum reaction
• Patients with allergies to human serum albumin antibiotics, trypsin
• Patients with severe blood disorders, heart failure, liver disorders, and renal disorders
• Patients diagnosed with malignant tumor within 5 years or patients requiring treatment

Sponsors & Collaborators

• PharmaBio Corporation: lead

Study Sites (1)

Yamaguchi University Hospital

Ube, Ymaguchi, 755-8505, Japan

RECRUITING

Study Officials

• Hitoshi Kusano, M.D.

  PhamaBio Coorporation

  STUDY CHAIR

Central Study Contacts

Hitoshi Hitoshi Kusano, M.D.

CONTACT

+81 44-589-6479; clinicaltrial@pharmabio.co.jp

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 3, 2025
• First Posted: June 5, 2025
• Study Start: September 12, 2024
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): March 1, 2027
• Last Updated: June 5, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

JP (1)